{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:13:00Z","timestamp":1786119180828,"version":"build-2736575974"},"reference-count":43,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1097\/cco.0b013e32830b61c2","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T16:53:39Z","timestamp":1236272019000},"page":"487-494","source":"Crossref","is-referenced-by-count":13,"title":["Dose-intense treatment of mantle cell lymphoma: can durable remission be achieved?"],"prefix":"10.1097","volume":"20","author":[{"given":"Martin","family":"Dreyling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210128","article-title":"Tumours of the haemopoietic and lymphoid tissues","author":"Jaffe","year":"2001"},{"key":"R2-2-20210128","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"R3-2-20210128","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"R4-2-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1535-6108(03)00028-X","article-title":"The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma","volume":"3","author":"Rosenwald","year":"2003","journal-title":"Cancer Cell"},{"key":"R5-2-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1365-2141.2005.05716.x","article-title":"Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network","volume":"131","author":"Tiemann","year":"2005","journal-title":"Br J Haematol"},{"key":"R6-2-20210128","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2005-10-4079","article-title":"The Ki67 proliferation index is a quantitative indicator of the clinical risk in mantle cell lymphoma","volume":"107","author":"Katzenberger","year":"2006","journal-title":"Blood"},{"key":"R7-2-20210128","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1182\/blood-2007-10-117010","article-title":"Ki-67 predicts outcome in advanced stage mantle cell lymphoma patients treated with anti-CD20 immunochemo-therapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group","volume":"111","author":"Determann","year":"2008","journal-title":"Blood"},{"key":"R8-2-20210128","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"key":"R9-2-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R10-2-20210128","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1200\/JCO.2002.20.5.1288","article-title":"Rituximab and CHOP induction therapy for newly diagnosed mantle cell lymphoma: molecular complete responses are not predictive of progression-free survival","volume":"20","author":"Howard","year":"2002","journal-title":"J Clin Oncol"},{"key":"R11-2-20210128","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2165\/00003495-200767120-00004","article-title":"Current management of mantle cell lymphoma","volume":"67","author":"Weigert","year":"2007","journal-title":"Drugs"},{"key":"R12-2-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00432-005-0023-2","article-title":"Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin's lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)","volume":"132","author":"Herold","year":"2006","journal-title":"J Cancer Res Clin Oncol"},{"key":"R13-2-20210128","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1200\/JCO.1998.16.5.1922","article-title":"Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group","volume":"16","author":"Hiddemann","year":"1998","journal-title":"J Clin Oncol"},{"key":"R14-2-20210128","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/cncr.22093","article-title":"CHOP improves response rates but not survival and has a lower hematologic toxicity as compared to MCP in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"107","author":"Nickenig","year":"2006","journal-title":"Cancer"},{"key":"R15-2-20210128","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1200\/JCO.2005.08.133","article-title":"Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"23","author":"Lenz","year":"2005","journal-title":"J Clin Oncol"},{"key":"R16-2-20210128","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"R18-2-20210128","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3324\/haematol.10608","article-title":"Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome","volume":"92","author":"Dreger","year":"2007","journal-title":"Haematologica"},{"key":"R19-2-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"R20-2-20210128","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"R21-2-20210128","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem cell transplantation as first line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert","year":"2006","journal-title":"Haematologica"},{"key":"R23-2-20210128","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"R25-2-20210128","doi-asserted-by":"crossref","first-page":"3803","DOI":"10.1200\/JCO.1998.16.12.3803","article-title":"Hyper-CVAD and high-dose methotrexate\/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle cell lymphoma","volume":"16","author":"Khouri","year":"1998","journal-title":"J Clin Oncol"},{"key":"R26-2-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00277-006-0193-2","article-title":"The hyper-CVAD-rituximab chemotherapy programme followed by high dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma","volume":"86","author":"Ritchie","year":"2007","journal-title":"Ann Hematol"},{"key":"R27-2-20210128","first-page":"1","article-title":"Effect of remission status and induction chemotherapy regimen on outcome of autologous stem cell transplantation for mantle cell lymphoma","volume":"29","author":"Till","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"R29-2-20210128","first-page":"LB1","article-title":"Mantle cell lymphoma can be cured by intensive immunochemotherapy with in vivo purged stem cell support: final report of the Nordic Lymphoma Group MCL2 Study.","volume":"110","author":"Geisler","year":"2007","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"Suppl 1","key":"R30-2-20210128","doi-asserted-by":"crossref","first-page":"584a","DOI":"10.1182\/blood.V104.11.584.584","article-title":"Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle cell lymphoma (MCL)","volume":"104","author":"Herold","year":"2004","journal-title":"Blood"},{"key":"R31-2-20210128","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","article-title":"The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group","volume":"104","author":"Forstpointner","year":"2004","journal-title":"Blood"},{"key":"R32-2-20210128","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1200\/JCO.2005.08.100","article-title":"Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma","volume":"23","author":"Rummel","year":"2005","journal-title":"J Clin Oncol"},{"key":"R33-2-20210128","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1093\/jnci\/djk152","article-title":"Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis","volume":"99","author":"Schulz","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"R34-2-20210128","first-page":"689a","article-title":"Activity of yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract #2452].2452].","volume":"106","author":"Younes","year":"2005","journal-title":"Blood"},{"issue":"18S","key":"R35-2-20210128","first-page":"430s","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL Network and the PLRG","volume":"24","author":"Weigert","year":"2006","journal-title":"Proc Am Soc Clin Oncol"},{"key":"R36-2-20210128","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"R38-2-20210128","first-page":"484","article-title":"Mantle cell lymphoma and other t(11;14) disorders: how biology can drive therapy.","volume":"476-","author":"Dreyling","year":"2006","journal-title":"ASCO Educational book"},{"key":"R40-2-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"R41-2-20210128","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"R42-2-20210128","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"R43-2-20210128","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"R44-2-20210128","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"},{"key":"R45-2-20210128","doi-asserted-by":"crossref","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","article-title":"Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma","volume":"24","author":"Fisher","year":"2006","journal-title":"J Clin Oncol"},{"key":"R46-2-20210128","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/sj.leu.2404511","article-title":"Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma","volume":"21","author":"Weigert","year":"2007","journal-title":"Leukemia"},{"key":"R47-2-20210128","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","article-title":"Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma","volume":"104","author":"Kaufmann","year":"2004","journal-title":"Blood"},{"key":"R49-2-20210128","doi-asserted-by":"crossref","first-page":"5347","DOI":"10.1200\/JCO.2005.13.466","article-title":"Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma","volume":"23","author":"Witzig","year":"2005","journal-title":"J Clin Oncol"},{"issue":"18S","key":"R50-2-20210128","first-page":"457s","article-title":"Phase 3 study of patients with relapsed, refractory mantle cell lymphoma treated with temsirolimus compared with investigator's choice therapy","volume":"26","author":"Hess","year":"2008","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e32830b61c2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:40:28Z","timestamp":1786038028000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200809000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e32830b61c2","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}